Delivery Order SPE2DB24D8001-SPE2DB25FKZDB
Award Date
1/30/25
Potential Completion Date
1/31/25
Potential Value
$5.8K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $11,049.12 firm fixed-price delivery order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medical products. This award is part of Dakota Drug's existing $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, under the ECAT Generation V Program. The contract has a period of...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKYUJ, was granted by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $5,532.37 firm fixed-price delivery order is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML, with a completion date of November 1, 2024. Dakota Drug, Inc. is the prime contractor and holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at...
This is a federal contract award by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,722.06 Firm Fixed Price Delivery Order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract has an ultimate completion date of February 5, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $8,928.05 firm fixed price delivery order is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. This award is not set aside and is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,867.25 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product. The award is not associated with a set-aside program. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop Support Medical's ECAT...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The award is a Firm Fixed Price Delivery Order contract with a ceiling value of $5,161.66 and a performance period extending through February 21, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $10,105.17, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The ultimate completion date for this contract is June 28, 2024. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at...
The Defense Logistics Agency (DLA) awarded a $5,601.75 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This contract, which does not have a set-aside designation, is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKYUV, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $8,500.69 delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, and has a firm fixed price. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's ECAT Generation V...
This federal contract award SPE2DX15D8003|SPE2DX24F7D9E was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The firm-fixed-price contract has a ceiling value of $5,788.47 and an ultimate completion date of May 24, 2024. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (IDC)...